TELIX QSAM INC.

$ Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149315224010683 Filed on March 20, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023

Balance Sheet

Concept	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.386M	$1.386M
YoY Change	515.41%	515.41%
Cash & Equivalents	$1.386M
Short-Term Investments
Other Short-Term Assets	$250.0K	$318.9K
YoY Change	79.4%	128.82%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$1.705M	$1.705M
YoY Change	367.68%	367.68%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$1.705M	$1.705M
Total Long-Term Assets	$0.00	$0.00
Total Assets	$1.705M	$1.705M
YoY Change	367.68%	367.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$569.9K	$569.9K
YoY Change	-23.51%	-23.51%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$7.500K	$7.500K
YoY Change	-98.34%	-98.34%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.033M	$1.033M
YoY Change	-34.63%	-34.63%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.033M	$1.033M
Total Long-Term Liabilities	$0.00	$0.00
Total Liabilities	$1.033M	$1.033M
YoY Change	-34.63%	-34.63%
SHAREHOLDERS EQUITY
Retained Earnings	-$40.16M
YoY Change	14.16%
Common Stock	$361.00
YoY Change	58.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$163.2K	$672.4K
YoY Change
Total Liabilities & Shareholders Equity	$1.705M	$1.705M
YoY Change	367.68%	367.68%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent		usd
CY2023Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts		usd
CY2022Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts		usd
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent		usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable		usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable		usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2022	us-gaap	Deferred Sales Inducement Cost Amortization Expense Accrued Interest DeferredSalesInducementCostAmortizationExpenseAccruedInterest		usd
CY2023	QSAM	Gain Loss On Conversion Of Convertible Debt GainLossOnConversionOfConvertibleDebt		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued		usd
CY2022	QSAM	Adjustments To Additional Paid In Capital Series A Preferred Stock Deemedl Dividends AdjustmentsToAdditionalPaidInCapitalSeriesAPreferredStockDeemedlDividends		usd
CY2022	QSAM	Adjustments To Additional Paid In Capital Series B Preferred Stock Contractual Deemed Dividends AdjustmentsToAdditionalPaidInCapitalSeriesBPreferredStockContractualDeemedDividends		usd
CY2022	QSAM	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits		usd
CY2023	QSAM	Adjustments To Additional Paid In Capital Series A Preferred Stock Deemedl Dividends AdjustmentsToAdditionalPaidInCapitalSeriesAPreferredStockDeemedlDividends		usd
CY2023	QSAM	Adjustments To Additional Paid In Capital Series B Preferred Stock Contractual Deemed Dividends AdjustmentsToAdditionalPaidInCapitalSeriesBPreferredStockContractualDeemedDividends		usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
CY2022	QSAM	Inducement Expense InducementExpense		usd
CY2023	QSAM	Gain On Conversion Of Convertible Debt GainOnConversionOfConvertibleDebt		usd
CY2023	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities		usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	QSAM	Incremental Value Of Series A Conversion Modifications IncrementalValueOfSeriesAConversionModifications		usd
CY2023	QSAM	Warrant Modification And Deemed Dividend WarrantModificationAndDeemedDividend		usd
CY2023	QSAM	Conversion Of Debentures And Notes Payable With Unrelated Parties To Common Stock ConversionOfDebenturesAndNotesPayableWithUnrelatedPartiesToCommonStock		usd
CY2023	QSAM	Conversion Of Accrued Salary And Bonus Director Fees And Notes Payable With Related Parties To Common Stock ConversionOfAccruedSalaryAndBonusDirectorFeesAndNotesPayableWithRelatedPartiesToCommonStock		usd
CY2022	us-gaap	Stock Issued1 StockIssued1		usd
CY2022	QSAM	Deferred Compensation For Employees And Consultants DeferredCompensationForEmployeesAndConsultants		usd
CY2022	QSAM	Subscription Receivable For Proceeds From Sale Of Common Stock SubscriptionReceivableForProceedsFromSaleOfCommonStock		usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes		usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes		usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities		usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities		usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity Registrant Name EntityRegistrantName	QSAM Biosciences, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity File Number EntityFileNumber	001-41337
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-1602779
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	9442 Capital of Texas Hwy N
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Plaza 1
CY2023	dei	Entity Address Address Line3 EntityAddressAddressLine3	Suite 500
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Austin
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	78759
CY2023	dei	City Area Code CityAreaCode	(512)
CY2023	dei	Local Phone Number LocalPhoneNumber	343-4558
CY2023	dei	Security12g Title Security12gTitle	Common Stock, par value $0.0001
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	6320000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	4445469	shares
CY2023	dei	Auditor Firm AuditorFirmId	5036
CY2023	dei	Auditor Name AuditorName	Assurance Dimensions
CY2023	dei	Auditor Location AuditorLocation	Margate, Florida
CY2023Q4	us-gaap	Cash Cash	1386387	usd
CY2022Q4	us-gaap	Cash Cash	225276	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	68860	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	139345	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	250000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1705247	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	364621	usd
CY2023Q4	us-gaap	Assets Assets	1705247	usd
CY2022Q4	us-gaap	Assets Assets	364621	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	569851	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	745011	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	79166	usd
CY2023Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	455548	usd
CY2022Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	304653	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1032899	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1580030	usd
CY2023Q4	us-gaap	Liabilities Liabilities	1032900	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1580030	usd
CY2023Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	1500	shares
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	1500	shares
CY2023Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	240	shares
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	240	shares
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	240	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	240	shares
CY2023Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	509198	usd
CY2022Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	721200	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	509198	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	721200	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1509	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1509	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1509	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1509	shares
CY2023Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	1964502	usd
CY2022Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	1813607	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	2	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	2	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3609382	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3609382	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2279019	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2279019	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	361	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	228	usd
CY2023Q4	us-gaap	Deferred Compensation Equity DeferredCompensationEquity	1345509	usd
CY2022Q4	us-gaap	Deferred Compensation Equity DeferredCompensationEquity	187329	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	41666897	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	33428115	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-40158601	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-35177625	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	163150	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1936609	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1705247	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	364621	usd
CY2023	us-gaap	Salaries And Wages SalariesAndWages	1001704	usd
CY2022	us-gaap	Salaries And Wages SalariesAndWages	2899987	usd
CY2023	us-gaap	Professional Fees ProfessionalFees	1533507	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	1262860	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	247306	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	275923	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1159993	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1022412	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	3942510	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	5461182	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-3942510	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-5461182	usd
CY2023	us-gaap	Financing Interest Expense FinancingInterestExpense	52688	usd
CY2022	us-gaap	Financing Interest Expense FinancingInterestExpense	74390	usd
CY2023	us-gaap	Deferred Sales Inducement Cost Amortization Expense Accrued Interest DeferredSalesInducementCostAmortizationExpenseAccruedInterest	397928	usd
CY2022	QSAM	Gain Loss On Conversion Of Convertible Debt GainLossOnConversionOfConvertibleDebt	54281	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-450616	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-20109	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4393126	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5481291	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4393126	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-5481291	usd
CY2023	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	27998	usd
CY2022	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	27620	usd
CY2023	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	150895	usd
CY2022	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	151310	usd
CY2023	QSAM	Deemed Dividend On Warrant Modification DeemedDividendOnWarrantModification	283685	usd
CY2022	QSAM	Deemed Dividend On Warrant Modification DeemedDividendOnWarrantModification	41225	usd
CY2023	QSAM	Deemed Dividends From Series A And B Conversion Price Reduction DeemedDividendsFromSeriesAAndBConversionPriceReduction	305541	usd
CY2022	QSAM	Deemed Dividends From Series A And B Conversion Price Reduction DeemedDividendsFromSeriesAAndBConversionPriceReduction	373435	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5161245	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6074881	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.69
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.69
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.45
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.45
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3046052	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3046052	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1762160	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1762160	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-416664	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	482162	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	113651	usd
CY2022	QSAM	Adjustments To Additional Paid In Capital Series A Preferred Stock Contractual Dividends AdjustmentsToAdditionalPaidInCapitalSeriesAPreferredStockContractualDividends	-27620	usd
CY2022	QSAM	Adjustments To Additional Paid In Capital Series B Preferred Stock Contractual Dividends AdjustmentsToAdditionalPaidInCapitalSeriesBPreferredStockContractualDividends	-151309	usd
CY2022	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	1534964	usd
CY2022	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	40:1 Reverse Split
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1402500	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	606998	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-5481291	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1936609	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1936609	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	850929	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1376	usd
CY2023	QSAM	Adjustments To Additional Paid In Capital Series A Preferred Stock Contractual Dividends AdjustmentsToAdditionalPaidInCapitalSeriesAPreferredStockContractualDividends	-27998	usd
CY2023	QSAM	Adjustments To Additional Paid In Capital Series B Preferred Stock Contractual Dividends AdjustmentsToAdditionalPaidInCapitalSeriesBPreferredStockContractualDividends	-150895	usd
CY2023	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	402577	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1164246	usd
CY2023	QSAM	Adjustments To Additional Paid In Capital Warrant Issued Cash AdjustmentsToAdditionalPaidInCapitalWarrantIssuedCash	2000000	usd
CY2023	QSAM	Stock Issued During Period Shares Exercise Of Warrants To Common Stock StockIssuedDuringPeriodSharesExerciseOfWarrantsToCommonStock	1095001	usd
CY2023	QSAM	Inducement For Conversion Of Convertible Debt InducementForConversionOfConvertibleDebt	397937	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	240000	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	519712	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4393126	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	163150	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	163150	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4393126	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-5481291	usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	852305	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	482162	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	402577	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1534964	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	36300	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	36300	usd
CY2023	QSAM	Inducement Expense InducementExpense	397937	usd
CY2022	QSAM	Gain On Conversion Of Convertible Debt GainOnConversionOfConvertibleDebt	-54281	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-70485	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4331	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-142604	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	155833	usd
CY2023	QSAM	Increase Decrease In Accrued Payroll And Related Expenses IncreaseDecreaseInAccruedPayrollAndRelatedExpenses	-79166	usd
CY2022	QSAM	Increase Decrease In Accrued Payroll And Related Expenses IncreaseDecreaseInAccruedPayrollAndRelatedExpenses	590763	usd
CY2023	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	7156	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	27791	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2848136	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2712090	usd
CY2022	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	35000	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1095001	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2000000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	914246	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1402500	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4009247	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1437500	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1161111	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1274590	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	225276	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1499866	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1386387	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	225276	usd
CY2023	QSAM	Accrual Of Contractual Dividends On Series Convertible Preferred Stock AccrualOfContractualDividendsOnSeriesConvertiblePreferredStock	27998	usd
CY2022	QSAM	Accrual Of Contractual Dividends On Series Convertible Preferred Stock AccrualOfContractualDividendsOnSeriesConvertiblePreferredStock	27620	usd
CY2023	QSAM	Accrual Of Contractual And Deemed Dividends On Series Convertible Preferred Stock AccrualOfContractualAndDeemedDividendsOnSeriesConvertiblePreferredStock	150895	usd
CY2022	QSAM	Accrual Of Contractual And Deemed Dividends On Series Convertible Preferred Stock AccrualOfContractualAndDeemedDividendsOnSeriesConvertiblePreferredStock	151309	usd
CY2023	QSAM	Incremental Value Of Series A Conversion Modifications IncrementalValueOfSeriesAConversionModifications	282309	usd
CY2022	QSAM	Warrant Modification And Deemed Dividend WarrantModificationAndDeemedDividend	41225	usd
CY2023	QSAM	Deemed Dividend On Series Conversion Price Modifications DeemedDividendOnSeriesConversionPriceModifications	96245	usd
CY2022	QSAM	Deemed Dividend On Series Conversion Price Modifications DeemedDividendOnSeriesConversionPriceModifications	342497	usd
CY2023	QSAM	Deemed Dividend On Series B Conversion Price Modifications DeemedDividendOnSeriesBConversionPriceModifications	209296	usd
CY2022	QSAM	Deemed Dividend On Series B Conversion Price Modifications DeemedDividendOnSeriesBConversionPriceModifications	30938	usd
CY2022	QSAM	Conversion Of Debentures And Notes Payable With Unrelated Parties To Common Stock ConversionOfDebenturesAndNotesPayableWithUnrelatedPartiesToCommonStock	35000	usd
CY2022	QSAM	Conversion Of Accrued Salary And Bonus Director Fees And Notes Payable With Related Parties To Common Stock ConversionOfAccruedSalaryAndBonusDirectorFeesAndNotesPayableWithRelatedPartiesToCommonStock	606981	usd
CY2023	QSAM	Conversion Of Convertible Debt And Accrued Interest To Common Stock ConversionOfConvertibleDebtAndAccruedInterestToCommonStock	519712	usd
CY2022	QSAM	Conversion Of Convertible Debt And Accrued Interest To Common Stock ConversionOfConvertibleDebtAndAccruedInterestToCommonStock	132934	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	240000	usd
CY2023	QSAM	Deferred Compensation For Employees And Consultants DeferredCompensationForEmployeesAndConsultants	1424384	usd
CY2023	QSAM	Subscription Receivable For Proceeds From Sale Of Common Stock SubscriptionReceivableForProceedsFromSaleOfCommonStock	250000	usd
CY2022Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	Company completed a 40:1 reverse stock split of its common shares.
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2848136	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4393126	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-40158601	usd
CY2023Q4	QSAM	Working Capital WorkingCapital	672348	usd
CY2023Q4	us-gaap	Cash Cash	1386387	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023Q4	QSAM	Directors Fees Paid Previously Accrued DirectorsFeesPaidPreviouslyAccrued	169216	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1159993	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1022412	usd
CY2022Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	all shares adjusted to reflect a 40:1 reverse stock split effected on March 9, 2022
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	988773	shares
CY2022Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	all shares adjusted to reflect a 40:1 reverse stock split effected on March 9, 2022
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1075051	shares
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_845_eus-gaap--UseOfEstimates_zTZzle9umVg8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_867_zgraCkbHFZ7c">Significant Estimates</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. Generally Accepted Accounting Principles (“GAAP”) requires the Company to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, the reported amounts of revenues and expenses, cash flows and the related footnote disclosures during the period. On an on-going basis, the Company reviews and evaluates its estimates and assumptions, including, but not limited to, those that relate to the fair value of stock-based compensation fair value of convertible bridge notes, and a valuation allowance on deferred tax assets and contingencies. Actual results could differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zW3GDB4jeGr2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_867_zN44QKR3iy6">Concentration of Risk</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company expects cash to be the asset most likely to subject the Company to concentrations of credit risk. The Company’s bank deposits may at times exceed federally insured limits. The Company’s policy is to maintain its cash with high credit quality financial institutions to limit its risk of loss exposure. The Company’s cash balance as of December 31, 2023 is in excess of FDIC limits in the amount of approximately $<span id="xdx_908_eus-gaap--CashUninsuredAmount_iI_c20231231_zLM0CIcuuMvi" title="Cash in excess of FDIC limits">1,136,387</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to a number of risks similar to those of other companies at a clinical-stage for radiopharmaceutical drug candidates, including dependence on key individuals; the need to develop commercially viable therapeutics; competition from other companies, many of which are larger and better capitalized; intellectual property risks; and the need to obtain adequate additional financing to fund the development of its products. The Company currently depends on third-party suppliers for key materials and services used in its research and development manufacturing process, and is subject to certain risks related to the loss of these third-party suppliers or their inability to supply the Company with adequate materials and services. The Company’s primary Technology is licensed from one party and is subject to general risks related to contractual relationships and the performance of the parties under the contract.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	1136387	usd
CY2022	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	30000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8625	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	101991	usd
CY2023	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1330363	shares
CY2022	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	626917	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.00
CY2023Q1	QSAM	Offset Fees OffsetFees	49500	usd
CY2023Q1	us-gaap	Common Stock Share Subscribed But Unissued Subscriptions Receivable CommonStockShareSubscribedButUnissuedSubscriptionsReceivable	342669	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	50000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	177815	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.57
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M18D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	27204	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	24.82
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue	0
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	150611	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.35
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M2D
CY2023	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	402577	usd
CY2022	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	1534964	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	166417	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-922556	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1151071	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	178984	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	423597	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	292	usd
CY2023	QSAM	Income Tax Reconciliation Gains Losses On Extinguishment Of Debt IncomeTaxReconciliationGainsLossesOnExtinguishmentOfDebt	91280	usd
CY2022	QSAM	Income Tax Reconciliation Gains Losses On Extinguishment Of Debt IncomeTaxReconciliationGainsLossesOnExtinguishmentOfDebt	-11399	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-78372	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	592659	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	730372	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	146214	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3605912	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3204894	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	211162	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	58106	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	369533	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	193236	usd
CY2023Q4	QSAM	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Charitable Contribution DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsCharitableContribution	221	usd
CY2022Q4	QSAM	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Charitable Contribution DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsCharitableContribution	221	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	4186828	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	3456457	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4186828	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3456457	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	4186828	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	3456457	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	17171010	usd
CY2023Q4	QSAM	Potential Tax Benefit Arising From Nols PotentialTaxBenefitArisingFromNols	6822000	usd
CY2023Q4	QSAM	Potential Tax Benefit Arising From Net Operating Loss Carryforward PotentialTaxBenefitArisingFromNetOperatingLossCarryforward	10349142	usd
CY2023	QSAM	Termination Agreement Description TerminationAgreementDescription	The employment agreements as amended for the Company’s Executive Chairman and CEO each contain termination provisions whereby if they are terminated without cause or following a material change, as defined therein, they will receive salary through the date of termination plus an additional 24 months, bonus that would be earned during the full year when the termination became effective (or a lump sum of 50% of the full target bonus), all stock options shall vest and healthcare benefits will continue for 24 months. The Company’s General Counsel’s employment agreement, as amended, contains an 18-month severance payment in the instance of a termination without cause or following a material change, as defined therein. In June 2023, the Company’s General Counsel was provided the additional title of Executive Vice President – Corporate Development.
CY2023	QSAM	Employment Agreements Description EmploymentAgreementsDescription	Pursuant to amendments dated November 14, 2022 to the three employment agreements of the Company’s Executive Chairman, CEO and EVP/General Counsel, as well as an amendment to the employment agreement for the Company’s VP Operations (the “2022 Amendments”), each of these four employees have agreed to accept reduced salaries until the Company is successful in raising additional funds. Specifically, when the Company raises at least $7.5 million in a single offering, each employee’s salary will be increased to the full contracted rate; and prior to that time, the reduced salaries will be gradually increased as the Company raises $2 million and then $5 million. During this time, the difference between the reduced salaries and the full contracted salaries will not accrue as liabilities for the Company.
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	0	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	79166	usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	5000000	usd
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	87083	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	82133	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Description And Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms	These shares vest 50% upon a Nasdaq listing of the Company’s stock if completed within three years, and 50% in eight quarterly installments upon the sooner of the Nasdaq listing or 12 months from issuance. All shares will vest upon the sale, merger or other “exit” event of the Company. Pursuant to Board resolutions as of August 21, 2023, Dr. Link was awarded a transaction bonus in the instance any of the Company’s assets are sold or sublicensed or if the Company or its subsidiary is acquired, equal to 0.75% of the consideration received by the Company, to compensate him for services he previously performed for the Company as interim medical director. In the fourth quarter of 2023, the Company paid a total of $169,217 of accrued directors’ compensation

Files In Submission

Name	View Source	Status
0001493152-24-010683-index-headers.html	Edgar Link	pending
0001493152-24-010683-index.html	Edgar Link	pending
0001493152-24-010683.txt	Edgar Link	pending
0001493152-24-010683-xbrl.zip	Edgar Link	pending
ex19.htm	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
fin_001.jpg	Edgar Link	pending
fin_002.jpg	Edgar Link	pending
fin_003.jpg	Edgar Link	pending
fin_004.jpg	Edgar Link	pending
fin_005.jpg	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
qsam-20231231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
qsam-20231231_cal.xml	Edgar Link	unprocessable
qsam-20231231_def.xml	Edgar Link	unprocessable
qsam-20231231_lab.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
qsam-20231231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

TELIX QSAM INC.

2024 Q1 Form 10-K Financial Statement

#000149315224010683 Filed on March 20, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission